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the OTT in the postoperative setting is less clear. Therefore, 
the main objective of this phase III study was to determine 
the value of reduction of the OTT of postoperative 
radiotherapy in high risk patients primarily treated with 
surgery.  
Materials and Methods: Patients with HNSCC treated with 
curative surgery and with high risk factors for locoregional 
recurrence (i.e., positive surgical margins and/or extranodal 
spread) were randomly assigned to receive either 
conventional postoperative radiotherapy (CON-RT) at 2 
Gy/fraction/day, 5 days/week to 66 Gy/33 fractions/7 weeks 
or postoperative accelerated radiotherapy (POPART) with 2 
Gy/fraction/day, 5 days per week, to 20 Gy followed by 1.8 
Gy/fraction/day and 1.3 Gy/fraction per day to a boost field 
as a second daily treatment to 66.5 Gy/40 fractions/5 
weeks.The primary endpoint was locoregional tumor control 
(LRC). Secondary endpoints were overall survival (OS), 
progression-free survival (PFS), acute and late toxicity and 
quality of life.  
Results: From November 2004 to August 2009, 148 patients 
were enrolled in the study (74 pts for CON-RT and 74 pts for 
POPART). The median follow up time was 6.2 years. The two 
study-arms were well balanced with regard to the most 
important prognostic factors. No significant differences were 
noted with regard to acute and late toxicity, although there 
was a trend towards more use of pain medication among 
patients treated with POPART. At 3 years, the LRC rate was 
76.5% (95% CI: 67.0-87.4) after POPART compared to 74.2% 
(95% CI: 64.6-85.0) with CON-RT (HR: 0.75, CI 0.40-1.43; 
p=0.39). No difference was found with regard to PFS (p=0.16) 
with a HR of 0.74 (95% CI: 0.49 - 1.13). The medians were 
42.6 (95%CI: 31-78.3) months for CON-RT and 60.5 (95%CI: 
34.6-NA) for POPART. The DFS probability at 8 years was 
43.8% for CON-RT (95% CI: 33.8-57.0) and 51% POPART (95% 
CI: 40.7-63.8). No statistical difference was noted in the long 
term between the two arms. The 8-year overall survival rate 
was 46.0% with POPART compared to 33.1% with CON-RT 
(HR:0.82, CI 0.53-1.28; p=0.39).  
Conclusions: A reduction in the OTT of postoperative 
radiotherapy in patients with HNSCC with adverse factors for 
locoregional failure does not improve outcome in terms of 
LRC, PFS and OS.  
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Purpose/Objective: To investigate the clinical value of the 
plasma EBV DNA (pEBV DNA) assay in patients with 
nasopharyngeal carcinoma (NPC) after curative treatment. 
Materials and Methods: The inclusion criteria for this multi-
center prospective study are (1)biopsy-proven NPC, (2)no 
distant metastasis, (3)finishing curative radiotherapy with 3 
years, (4)no clinically detectable active diseases. pEBV DNA 
concentration is monitored every 3 months. Detailed staging 
workups are performed when abnormal pEBV DNA detected. 
All tumor recurrences are documented by imaging studies 
along with pathological verification if the lesions are 
accessible and patients agree. 
Results: From August 2011 to December 2013, 441 patients 
were enrolled and 69 patients had abnormal pEBV DNA during 
follow-up visit. Sixty-three of 69 (91.3%) patients with 
elevated pEBV DNA have been proven as tumor relapse, 
whereas only 4 of 368 (1.1%) patients with normal pEBV DNA 
level are showing tumor relapse (P<0.001). In addition, most 
(60.3%) relapsed patients were detected in a symptomless 
state. Patients with elevated pEBV DNA during follow-up had 
significant worse overall survival than those with 
undetectable pEBV DNA (P<0.001). 
Conclusions: pEBV DNA is a reliable biomarker in early 
detection of tumor relapse in post-treatment NPC patients 
monitoring with a very high positive predictive value (91.3%) 
and negative predictive value (98.9%).  
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Purpose/Objective: Induction chemotherapy with docetaxel, 
cisplatin, and 5 FU (TPF) before radiotherapy (RT) or radio-
chemotherapy (RT-CHX) has been shown to improve overall 
survival compared to induction chemotherapy with cisplatin 
and 5 FU in locally advanced squamous cell carcinoma of the 
head and neck (SCCHN). Whether TPF induction before RT-
CHX improves clinical outcome in comparison to RT-CHX 
alone is still a matter of debate. Recently, the results of 5 
randomized trials addressing this question have become 
available. 
Materials and Methods: In the 5 trials of interest, in total 
1060 patients with locally advanced SCCHN were randomly 
assigned to receive either TPF induction CHX followed by 
concurrent RT-CHX or concurrent RT-CHX alone. Platin or 
taxane based CHX was used during RT. 53,4% of patients had 
oropharyngeal, 17,3% hyopharyngeal, 6,4% laryngeal, 18,5% 
oral cavity and 4,4% other SCCHN. Published hazard ratios 
and hazard ratios extracted from available survival curves for 
overall survival (OS) and progression free survival (PFS) were 
basis of the meta-analysis. Meta-analysis of the effect sizes 
on OS and PFS was performed using a random effects model 
based on parameter estimates of log hazard ratios in Cox 
models and their standard errors.  
Results: Additional induction CHXwith TPF before RT-CHX did 
not result in a significant improvement of overall survival 
(Hazard Ratio: 0.950, 95% confidence limits (CL) 0.791-1.140 
p=0.579).  
Conclusions: Additional induction CHX with TPF before RT-
CHX does not improve overall survival in SCCHN.  
